Literature DB >> 2174987

[Successful high-dose methylprednisolone therapy in a patient with primary myelofibrosis].

Y Matsukawa1, E Ikeda, H Suguro, Y Iizuka, S Nishinarita, T Hayama, T Ohshima, S Sawada, T Horie.   

Abstract

We are presenting a patient with primary myelofibrosis who responded to the High-Dose methylprednisolone therapy (1 g/day for 3 days). Three and a half years ago, a 55-year-old male was admitted to our hospital because of severe erythroblastic anemia, thrombocytopenia, splenomegaly and "dry tap" of bone marrow aspiration. Bone marrow biopsy revealed a marked fibrosis without any blastoid cell proliferations. Since a thrombocytopenia was progressive and refractory to the ordinary therapy, high-dose methylprednisolone therapy was performed which was followed by an administration of activated vitamin D3. After the therapy, hematologic improvements were achieved within a month (RBC: 284 x 10(4)/microliters----413 x 10(4)/microliters, WBC: 3,000/microliters----11,500/microliters, Plat.: 7,000/microliters----20,000/microliters). Three months after the therapy, the bone marrow biopsy and 113In scintigraphy were performed. These tests also proved marked improvement of histological features of the bone marrow and a decrease of uptake of 113In to the spleen, respectively. The patient continues to be in good condition and he is free from any medications at present time.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174987

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

1.  A pleural effusion caused by fibrous hematopoietic tumor successfully treated with prednisolone in a patient with agnogenic myeloid metaplasia with myelofibrosis.

Authors:  Yasuo Hirayama; Ryuzo Koyama; Tadanori Nagai; Takuya Matsunaga; l Katsuhisa Kogawa; Sumio Sakamaki; Yasuo Kokai; Yoshiro Niitsu
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.